Albireo Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel bile acid modulators to treat rare pediatric liver diseases. The company's flagship product, odevixibat, is a potent and selective IBAT inhibitor designed to treat Progressive Familial Intrahepatic Cholestasis (PFIC), a rare genetic liver disease. Albireo operates in the biopharmaceutical market, targeting orphan liver diseases with no currently approved drug therapies. The business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary drugs. Revenue is generated through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies. Albireo serves patients, healthcare providers, and the broader medical community, aiming to alleviate the pain and suffering associated with bile acid biology irregularities.

Keywords: biopharmaceutical, bile acid modulators, pediatric liver diseases, PFIC, odevixibat, IBAT inhibitor, orphan diseases, clinical trials, drug development, rare genetic disorders.